Sakara Digital https://validator.w3.org/feed/docs/rss2.html The Velocity of Lasting Change, Part 1 – The Funeral of Innovation Building with GenAI: A Founder’s Journey, Part 1 – Why We’re Using AI to Help Build Sakara Digital The Velocity of Lasting Change, Part 2 – The Cost of Compliance Building with GenAI: A Founder’s Journey, Part 2 – From Idea to Offering, Defining a Managed Service for a Potential Customer The Velocity of Lasting Change, Part 3 – The Myth of Readiness Implementing a Global Quality Management System (QMS), Part 1 – Lessons from the Field Understanding AI Maturity: Part 1 – The AI Maturity Model – From Ad Hoc to Enterprise Ecosystems Building with GenAI: A Founder’s Journey Part 3: Messaging, Branding, and the AI Co-Creation Process Understanding AI Maturity: Part 2 – Stage 1: Ad Hoc Use – Where Curiosity Meets Risk Implementing a Global Quality Management System (QMS): Part 2 – Lessons from the Field Understanding AI Maturity: Part 3 – Stage 2: Localized Projects Understanding AI Maturity: Part 4 – Stage 3: Programmatic Use Understanding AI Maturity: Part 5 – Stage 4: Enterprise Ecosystems Rethinking Training—How Digital Adoption Solutions Are Changing the Game Code Without Compassion, Part 1: Fired by Bot — The Amazon Flex Case From Compliance to AI—The Expanding Power of Digital Adoption Platforms Code Without Compassion, Part 2: When Algorithms Manage Humans Code Without Compassion, Part 3: Due Process in the Age of AI Where Are You in The AI Maturity Model? Inspection Readiness Is a Mindset What is a Digital Adoption Solution Code Without Compassion, Part 4: Designing for Dignity Code Without Compassion, Part 5: What Businesses Can Learn Data Quality & Culture For AI Readiness The Hidden Risks of Poor Data Quality in Pharma: Regulatory, Operational, and AI Failures Fixing the Foundations: How Pharma Can Remediate Common Data Quality Issues Establishing an AI Policy: A Comprehensive White Paper for Life Sciences Teams A Roadmap for AI Readiness in Pharma: Building the Foundations for Trustworthy, Scalable AI Built-In, Not Bolted On: The Case for Native Digital Adoption in Life Sciences Software Choosing the Right Data Governance Model for Pharma: Centralized, Decentralized, or Federated? The ROI of Data Quality: How Strong Data Foundations Drive Innovation, Efficiency, and Compliance in Pharma Cloud-Based Supply Chain Integration for Life Sciences: Connecting ERP, WMS, and Serialization The Purolea Letter: What Pharma’s First AI Warning Means for GxP Compliance Building the AI Business Case in Pharma: What Leadership Needs to See Measuring ROI from AI Investments in Life Sciences AI Strategy Roadmap for Pharma Executives: From Vision to Execution Moving from AI Pilot to Enterprise Scale in Regulated Environments Why Most Pharma AI Investments Underperform (And How to Change That) The 10/20/70 Rule: Why Pharma AI Success Is 70% People and Process AI Vendor Selection Guide for Regulated Life Sciences Environments How to Write an AI Strategy That Gets Board Approval in Life Sciences Good AI Practice (GAIP): What the FDA/EMA Joint Guidance Means for Your QMS AI Governance Framework for Pharma QA Teams Risk-Based AI Validation in GxP Environments: A Practical Guide How to Build an AI Change Control Process in Regulated Systems Periodic Review for AI Systems: What GxP Requires 21 CFR Part 11 in the Age of AI: What Still Applies Computer System Validation vs. AI Validation: Key Differences That Matter Adaptive Trial Designs in 2026: When and How to Use Them AI-Powered Patient Recruitment: Strategies That Reduce Startup Time